Aims and objectives of this presentation
Gallium-PSMA PET is suggested to be an emerging tool in staging of prostate cancer. Conflicting data, however, have been published concerning its use for lymph node staging or diagnosis of prostate cancer relapse. This session will highlight the most recent data on new PET tracers for prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

14:23 - 14:33
Is seeing more enough to do more?
T. Wiegel, Ulm (DE)

Localization of primary prostate cancer by simultaneous 68Gallium-HBED-CC-PSMA PET and multiparametric MRI
By: Eiber M.¹, Weirich G.², Nguyen N.³, Holzapfel K.⁴, Souvatzoglou M.¹, Haller B.³, Rauscher I.¹, Beer A.⁴, Wester H.-J.⁵, Westenfelder K.³, Gschwend J.², Schwaiger M.¹, Maurer T.³
Institutes:¹ Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, ²Technical University of Munich, Dept. of Pathology, Munich, Germany, ³Technical University of Munich, Dept. of Urology, Munich, Germany, ⁴Technical University of Munich, Dept. of Radiology, Munich, Germany, ⁵Technical University of Munich, Dept. of Medical Statistics and Epidemiology, Munich, Germany, ⁶University of Ulm, Dept. of Nuclear Medicine, Ulm, Germany, ⁷Technical University of Munich, Dept. of Pharmaceutical Radiopharmacy, Munich, Germany

Diagnostic efficacy of 68Ga-PSMA PET for lymph node staging and metastatic distribution in patients with intermediate to high-risk prostate cancer
By: Maurer T.¹, Gschwend J.², Pähr L.¹, Rauscher I.², Souvatzoglou M.², Haller B.³, Weirich G.⁴, Wester H.-J.⁵, Heck M.¹, Hacker C.¹, Kübler H.¹, Beer A.⁴, Schwaiger M.², Eiber M.²
Institutes:¹ Technical University of Munich, Dept. of Urology, Munich, Germany, ²Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, ³Technical University of Munich, Institute for Medical Statistics and Epidemiology, Munich, Germany, ⁴Technical University of Munich, Institute of Pathology, Munich, Germany, ⁵Technical University of Munich, Dept. of Pharmaceutical Radiochemistry, Munich, Germany, ⁶University of Ulm, Dept. of Nuclear Medicine, Ulm, Germany

Prospective evaluation of 68Ga-PSMA positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer
By: Van Leeuwen P.¹, Emmett L.², Ho B.², Delprado W.², Stricker P.¹
Institutes:¹ St. Vincent’s Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, ²St. Vincent’s Public Hospital, Dept. of Diagnostic Imaging, Sydney, Australia, ³University of Notre Dame, Dept. of Histopathology, Sydney, Australia

68Ga-PSMA PET/CT provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer
By: Herlemann A.¹, Wenter V.², Kretschmer A.¹, Bartenstein P.², Stief C.¹, Gratzeck C.¹, Fendler W.²
Institutes: Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, Ludwig-Maximilians-University Munich, Dept. of Nuclear Medicine, Munich, Germany

**561**

Evaluation of detection rate of 68Ga-PSMA PET/CT for biochemical recurrence after radical prostatectomy

By: Paffen M.1, J.E.1, Murphy D.2, Costello A.2, Hicks R.3, Hoffman M.3

Institutes: Royal Melbourne Hospital, Dept. of Urology, Wodonga, Australia, Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, Peter MacCallum Cancer Centre, Dept. of Nuclear Medicine, Melbourne, Australia

**562**

Accuracy of 18f-fabc (anti1-amino-3-18f-fluorocyclobutane-1-carboxylic acid) in prostate cancer relapse: Results of a prospective trial

By: Pultrone C.V.1, Bianchi L.1, Brunociella E.2, Fanti S.2, Nanni C.2, Zanoni L.2, Matti A.2, Borghesi M.3, Bravi C.1, Martorana G.1, Schiavina R.1

Institutes: St Orsola Hospital, University of Bologna, Dept. of Urology, Bologna, Italy, St Orsola Hospital, University of Bologna, Dept. of Nuclear Medicine, Bologna, Italy, St Orsola Hospital, University of Bologna, Dept. of Urology and Medical and Surgical Sciences, Bologna, Italy

**563**

The diagnostic accuracy of 68Ga-PSMA-PET/CT for detection of lymph node metastases in the setting of salvage lymph node dissection

By: Jilg C.A.1, Drendel V.2, Beck T.3, Rischke C.3, Grosu A.4, Werner M.2, Wetterauer U.1, Meyer P.3, Schultz-Seemann W.1

Institutes: University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, University Medical Center Freiburg, Dept. of Pathology, Freiburg, Germany, University Medical Center Freiburg, Dept. of Nuclear Medicine, Freiburg, Germany, University Medical Center Freiburg, Dept. of Radiation Oncology, Freiburg, Germany

**564**

The role of 68Ga-PSMA PET/CT in the diagnosis and therapeutic decision making of oligometastatic recurrence after radical prostatectomy

By: Tosco L.1, Gheysens O.2, Deroose C.2, De Meerleer G.3, Haustermans K.4, Everaerts W.1, Cromphout L.1, Van Poppel H.1, Van Laere K.2, Joniau S.1, Goffin K.2

Institutes: UZ Leuven, Dept. of Development and Regeneration, Leuven, Belgium, UZ Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, University Hospitals Ghent, Dept. of Radiotherapy, Ghent, Belgium, UZ Leuven, Dept. of Radiotherapy, Leuven, Belgium

**565**

Probability of positive PET imaging with a [68Ga]-labelled PSMA ligand based on PSA value in patients with biochemical recurrent prostate cancer after radical prostatectomy

By: Cromphout L.1, Tosco L.1, Everaerts W.1, Albersen M.1, Gheysens O.2, Deroose C.2, Van Laere K.2, Goffin K.2, Joniau S.1

Institutes: UZ Leuven, Dept. of Urology, Leuven, Belgium, UZ Leuven, Dept. of Nuclear Medicine, Leuven, Belgium

**566**

68Gallium-HBED-CC-PSMA PET compared to conventional bone scintigraphy for evaluation of bone metastases in prostate cancer patients

By: Eiber M.1, Pyka T.1, Okamoto S.1, Rauscher I.1, Dahlbender M.2, Tauber R.2, Retz M.2, Gschwend J.2, Schwaiger M.1, Maurer T.2

Institutes: Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, Technical University of Munich, Dept. of Urology, Munich, Germany

**567**

PET imaging of therapy-naïve primary prostate cancer patients using the GRPr-targeting ligand Sarabesin 3

By: Bakker I.L.1, Fröberg A.C.1, Busstra M.B.2, Van Leenders G.J.L.H.2, De Blois E.1, Schoots I.4, Veenland J.4, Mina T.4, Van Weerden W.M.2, Nock B.A.4, De Jong M.1

Institutes: Erasmus MC, Dept. of Nuclear Medicine, Rotterdam, The Netherlands, Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, NCSR “Demokritos”, Dept. of Radiochemistry, Athens, Greece
PSMA pet improves diagnostic accuracy of mpMRI in localised prostate cancer as confirmed by whole mount histopathology: Implications for selection and assessment for active surveillance and focal therapy

By: Rhee H.¹, Thomas P.², Shepherd B.³, Greenslade S.⁴, Vela I.¹, Russell P.⁵, Nelson C.⁵, Chung E.⁶, Wood G.⁷, Malone G.⁸, Wood S.⁸, Heathcote P.⁸

Institutes: ¹Princess Alexandra Hospital/ Queensland University of Technology, Dept. of Urology and Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia, ²Royal Brisbane and Women’s Hospital, Dept. of Nuclear Medicine, Brisbane, Australia, ³Princess Alexandra Hospital, Dept. of Anatomical Pathology, Woolloongabba, Australia, ⁴Princess Alexandra Hospital, Dept. of Radiology, Woolloongabba, Australia, ⁵Queensland University of Technology, Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia, ⁶Princess Alexandra Hospital, Dept. of Urology, Woolloongabba, Australia, ⁷Greenslopes Private Hospital, Dept. of Urology, Brisbane, Australia, ⁸Princess Alexandra Hospital/Greenslopes Private Hospital, Dept. of Urology, Brisbane, Australia